Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: New perspectives and therapeutic potential

Cardiovascular Research

Volumn 63, Issue 1, 2004, Pages 11-21

  Andrés, Vicente ^a  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

Author keywords

CDK; Migration; Vascular cell proliferation

Indexed keywords

2 BIS(2 HYDROXYETHYL)AMINO 9 ISOPROPYL 6 (4 METHOXYBENZYLAMINO)PURINE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLINE; CYTOSTATIC AGENT; FLAVOPIRIDOL; HOLOENZYME; MIMOSINE; QUERCETIN; RAPAMYCIN; SURAMIN; TROGLITAZONE;

ARTERY INTIMA PROLIFERATION; ARTERY WALL; CARCINOMA CELL; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; ENZYME ACTIVATION; GENE THERAPY; INFLAMMATION; INTIMA; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ARTERIOSCLEROSIS; CELL DIVISION; CELL MOVEMENT; CYCLIN-DEPENDENT KINASES; CYCLINS; ENDOTHELIUM, VASCULAR; HUMANS; SIGNAL TRANSDUCTION; TUNICA INTIMA;

EID: 2942612344     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.02.009     Document Type: Review

References (142)

1. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340:1999;115-126
2. Lusis A.J. Atherosclerosis. Nature. 407:2000;233-241
3. Binder C.J., Chang M.K., Shaw P.X., et al. Innate and acquired immunity in atherogenesis. Nat. Med. 8:2002;1218-1226
4. Greaves D.R., Channon K.M. Inflammation and immune responses in atherosclerosis. Trends Immunol. 23:2002;535-541
5. Rivard A., Andrés V. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol. Histopathol. 15:2000;557-571
6. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8:2002;1249-1256
7. Burrig K.F. The endothelium of advanced arteriosclerotic plaques in humans. Arterioscler. Thromb. 11:1991;1678-1689
8. Gordon D., Reidy M.A., Benditt E.P., Schwartz S.M. Cell proliferation in human coronary arteries. Proc. Natl. Acad. Sci. U. S. A. 87:1990;4600-4604
9. Katsuda S., Coltrera M.D., Ross R., Gown A.M. Human atherosclerosis: IV. Immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am. J. Pathol. 142:1993;1787-1793
10. Kearney M., Pieczek A., Haley L., et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 95:1997;1998-2002
11. O'Brien E.R., Alpers C.E., Stewart D.K., et al. Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ. Res. 73:1993;223-231
12. Orekhov A.N., Andreeva E.R., Mikhailova I.A., Gordon D. Cell proliferation in normal and atherosclerotic human aorta: proliferative splash in lipid-rich lesions. Atherosclerosis. 139:1998;41-48
13. Rekhter M.D., Gordon D. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am. J. Pathol. 147:1995;668-677
14. Tanner F.C., Yang Z.-Y., Duckers E., Gordon D., Nabel G.J., Nabel E.G. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. 82:1998;396-403
15. Veinot J.P., Ma X., Jelley J., O'Brien E.R. Preliminary clinical experience with the pullback atherectomy catheter and the study of proliferation in coronary plaques. Can. J. Cardiol. 14:1998;1457-1463
16. Wei G.L., Krasinski K., Kearney M., Isner J.M., Walsh K., Andrés V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ. Res. 80:1997;418-426
17. Pickering J.G., Weir L., Jekanowski J., Kearney M.A., Isner J.M. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J. Clin. Invest. 91:1993;1469-1480
18. O'Brien E.R., Urieli-Shoval S., Garvin M.R., et al. Replication in restenotic atherectomy tissue. Atherosclerosis. 152:2000;117-126
19. Dartsch P.C., Voisard R., Bauriedel G., Hofling B., Betz E. Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary stenosing and restenosing lesions. Arteriosclerosis. 10:1990;62-75
20. Spraragen S.C., Bond V.P., Dahl L.K. Role of hyperplasia in vascular lesions of cholesterol-fed rabbits studied with thymidine-3H autoradiography. Circ. Res. 11:1962;329-336
21. McMillan G.C., Stary H.C. Preliminary experience with mitotic activity of cellular elements in the atherosclerotic plaques of cholesterol-fed rabbits studied by labeling with tritiated thymidine. Ann. N.Y. Acad. Sci. 149:1968;699-709
22. Rosenfeld M.E., Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis. 10:1990;680-687
23. Libby P., Tanaka H. The molecular basis of restenosis. Prog. Cardiovasc. Dis. 40:1997;97-106
24. Vidal A., Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene. 247:2000;1-15
25. Stevaux O., Dyson N.J. A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell Biol. 14:2002;684-691
26. Ubersax J.A., Woodbury E.L., Quang P.N., et al. Targets of the cyclin-dependent kinase Cdk1. Nature. 425:2003;859-864
27. Abe J., Zhou W., Taguchi J., et al. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun. 198:1994;16-24
28. Braun-Dullaeus R.C., Mann M.J., Seay U., et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler. Thromb. Vasc. Biol. 21:2001;1152-1158
29. Kip1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularity. Atherosclerosis. 144:1999;7-14
30. Nathe T.J., Deou J., Walsh B., Bourns B., Clowes A.W., Daum G. Interleukin-1beta inhibits expression of p21(WAF1/CIP1) and p27(KIP1) and enhances proliferation in response to platelet-derived growth factor-BB in smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 22:2002;1293-1298
31. Kip1. Circulation. 102:2000;2124-2130
32. Ii M., Hoshiga M., Fukui R., et al. Beraprost sodium regulates cell cycle in vascular smooth muscle cells through cAMP signaling by preventing down-regulation of p27(Kip1). Cardiovasc. Res. 52:2001;500-508
33. Takahashi A., Taniguchi T., Ishikawa Y., Yokoyama M. Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53. Circ. Res. 84:1999;543-550
34. Brooks G., Yu X.M., Wang Y., Crabbe M.J., Shattock M.J., Harper J.V. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit vascular smooth muscle cell proliferation via differential effects on the cell cycle. J. Pharm. Pharmacol. 55:2003;519-526
35. waf1cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 98:2001;12802-12807
36. Sato J., Nair K., Hiddinga J., et al. eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovasc. Res. 47:2000;697-706
37. Laufs U., Marra D., Node K., Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of p27(Kip1). J. Biol. Chem. 274:1999;21926-21931
38. Ashton A.W., Watanabe G., Albanese C., Harrington E.O., Ware J.A., Pestell R.G. Protein kinase Cdelta inhibition of S-phase transition in capillary endothelial cells involves the cyclin-dependent kinase inhibitor p27(Kip1). J. Biol. Chem. 274:1999;20805-20811
39. Chen D., Walsh K., Wang J. Regulation of cdk2 activity in endothelial cells that are inhibited from growth by cell contact. Arterioscler. Thromb. Vasc. Biol. 20:2000;629-635
40. Otterbein L.E., Zuckerbraun B.S., Haga M., et al. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat. Med. 9:2003;183-190
41. Sdi1/Cip1/Waf1. Circ. Res. 86:2000;185-190
42. Waf1/Cip1/Sdi1 mediates shear stress-dependent antiapoptotic function. Cardiovasc. Res. 61:2004;693-704
43. Kip1 regulation and cell cycle entry in vascular smooth muscle cells. 2003; 108: p. 616-22
44. Kip1 expression in the vasculature of hypertensive rats. Circ. Res. 89:2001;488-495
45. Kip1, an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. 99:1997;2334-2341
46. Roque M., Cordón-Cardo C., Fuster V., Reis E.D., Drobnjak M., Badimón J.J. Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model. Atherosclerosis. 153:2000;315-322
47. Reis E.D., Roque M., Cordón-Cardo C., Drobnjak M., Fuster V., Badimón J.J. Apoptosis, proliferation, and p27 expression during vessel wall healing: time course study in a mouse model of transluminal femoral artery injury. J. Vasc. Surg. 32:2000;1022-1029
48. Cip1 in human atherectomy specimens: primary stenosis versus restenosis. J. Lab. Clin. Med. 141:2003;179-189
49. Ihling C., Menzel G., Wellens E., Monting J.S., Schaefer H.E., Zeiher A.M. Topographical association between the cyclin-dependent kinases inhibitor p21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue. Arterioscler. Thromb. Vasc. Biol. 17:1997;2218-2224
50. Kip1 protects against diet-induced atherosclerosis. FASEB J. 15:2001;1989-1995
51. Kip1 in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. Blood. 103:2004;158-161
52. Kip1. Nat. Med. 6:2000;1235-1240
53. Kip1 regulatory checkpoint. J. Clin. Invest. 99:1997;2867-2876
54. Waf1. Blood. 98:2001;2124-2133
55. Roque M., Reis E.D., Cordon-Cardo C., et al. Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. Lab. Invest. 81:2001;895-903
56. Bochaton-Piallat M.L., Ropraz P., Gabbiani F., Gabbiani G. Phenotypic heterogeneity of rat arterial smooth muscle cell clones. Implications for the development of experimental intimal thickening. Arterioscler. Thromb. Vasc. Biol. 16:1996;815-820
57. Chamley-Campbell J.H., Campbell G.R., Ross R. Phenotype-dependent response of cultured aortic smooth muscle to serum mitogens. J. Cell Biol. 89:1981;379-383
58. Li S., Fan Y.S., Chow L.H., et al. Innate diversity of adult human arterial smooth muscle cells: cloning of distinct subtypes from the internal thoracic artery. Circ. Res. 89:2001;517-525
59. Majack R.A., Grieshaber N.A., Cook C.L., et al. Smooth muscle cells isolated from the neointima after vascular injury exhibit altered responses to platelet-derived growth factor and other stimuli. J. Cell Physiol. 167:1996;106-112
60. Topouzis S., Majesky M.W. Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-β Dev. Biol. 178:1996;430-445
61. Yang Z., Oemar B.S., Carrel T., Kipfer B., Julmy F., Lüscher T.F. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation. 97:1998;181-187
62. Olson N.E., Kozlowski J., Reidy M.A. Proliferation of intimal smooth muscle cells. Attenuation of basic fibroblast growth factor 2-stimulated proliferation is associated with increased expression of cell cycle inhibitors. J. Biol. Chem. 275:2000;11270-11277
63. Kip1 in smooth muscle cells from different vascular beds. A potential role in establishing regional phenotypic variance. J. Biol. Chem. 278:2003;4482-4490
64. Kavurma M.M., Khachigian L.M. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J. Cell Biochem. 89:2003;289-300
65. O'Sullivan M., Scott S.D., McCarthy N., et al. Differential cyclin E expression in human in-stent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy. Cardiovasc. Res. 60:2003;673-683
66. Brooks E.E., Gray N.S., Joly A., et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272:1997;29207-29211
67. Losiewicz M.D., Carlson B.A., Kaur G., Sausville E.A., Worland P.J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201:1994;589-595
68. Carlson B.A., Dubay M.M., Sausville E.A., Brizuela L., Worland P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56:1996;2973-2978
69. Ruef J., Meshel A.S., Hu Z., et al. Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat. Circulation. 100:1999;659-665
70. Morishita R., Gibbons G.H., Ellison K.E., et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J. Clin. Invest. 93:1994;1458-1464
71. Morishita R., Gibbons G.H., Ellison K.E., et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8474-8478
72. Morishita R., Gibbons G.H., Kaneda Y., Ogihara T., Dzau V.J. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene. 149:1994;13-19
73. Zhu N.L., Wu L., Liu P.X., et al. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation. 96:1997;628-635
74. Mann M., Gibbons G.H., Kernoff R.S., et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4502-4506
75. Suzuki J.-I., Isobe M., Morishita R., et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat. Med. 3:1997;900-903
76. Gascón-Irún M., Sanz-González S.M., Andrés V. Gene therapy antiproliferative strategies against cardiovascular disease. Gene Ther. Mol. Biol. 7:2003;75-89
77. Chang M.W., Barr E., Lu M.M., Barton K., Leiden J.M. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96:1995;2260-2268
78. Ueno H., Masuda S., SNishio S., Li J.J., Yamamoto H., Takeshita A. Adenovirus-mediated transfer of cyclin-dependent kinase inhibitor p21 suppresses neointimal formation in the balloon-injured rat carotid arteries in vivo. Ann. N.Y. Acad. Sci. 811:1997;401-411
79. Yang Z.-Y., Simari R.D., Perkins N.D., et al. Role of p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. U. S. A. 93:1996;7905-7910
80. Ink4 on vascular smooth muscle cell proliferation. Circulation. 101:2000;2022-2025
81. Kip2, suppressed vascular smooth muscle cell proliferation. Hokkaido Igaku Zasshi. 77:2002;221-230
82. Condorelli G., Aycock J.K., Frati G., Napoli C. Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice. FASEB J. 15:2001;2162-2170
83. Bai H., Morishita R., Kida I., et al. Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther. 5:1998;761-769
84. Lamphere L., Tsui L., Wick S., et al. Novel chimeric p16 and p27 molecules with increased antiproliferative activity for vascular disease gene therapy. J. Mol. Med. 78:2000;451-459
85. Tsui L.V., Camrud A., Mondesire J., et al. p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion. Circ. Res. 89:2001;323-328
86. McArthur J.G., Qian H., Citron D., et al. p27-p16 chimera: a superior antiproliferative for the prevention of neointimal hyperplasia. Mol. Ther. 3:2001;8-13
87. Marx S.O., Jayaraman T., Go L.O., Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 76:1995;412-417
88. Poon M., Marx S.O., Gallo R., Badimon J.J., Taubman M.B., Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. 98:1996;2277-2283
89. Alcocer F., Whitley D., Salazar-Gonzalez J.F., et al. Quercetin inhibits human vascular smooth muscle cell proliferation and migration. Surgery. 131:2002;198-204
90. Kubens B.S., Niggemann B., Zanker K.S. Prevention of entrance into G2 cell cycle phase by mimosine decreases locomotion of cells from the tumor cell line SW480. Cancer Lett. 162:2001;S39-S47. (Suppl)
91. Hu Y., Zou Y., Dietrich H., Wick G., Xu Q. Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation. 100:1999;861-868
92. Law R.E., Meehan W.P., Xi X.-P., et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98:1996;1897-1905
93. Geraldes P., Sirois M.G., Bernatchez P.N., Tanguay J.F. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 22:2002;1585-1590
94. Biro S., Fu Y.-M., Yu Z.-X., Epstein S.E. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc. Natl. Acad. Sci. U. S. A. 90:1993;654-658
95. Ahn J.D., Morishita R., Kaneda Y., et al. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ. Res. 90:2002;1325-1332
96. Mayr U., Mayr M., Li C., et al. Loss of p53 accelerates neointimal lesions of vein bypass grafts in mice. Circ. Res. 90:2002;197-204
97. Bonneton C., Sibarita J.B., Thiery J.P. Relationship between cell migration and cell cycle during the initiation of epithelial to fibroblastoid transition. Cell Motil. Cytoskeleton. 43:1999;288-295
98. Fukui R., Amakawa M., Hoshiga M., et al. Increased migration in late G(1) phase in cultured smooth muscle cells. Am. J. Physiol. Cell Physiol. 279:2000;C999-C1007
99. Cho R.J., Huang M., Campbell M.J., et al. Transcriptional regulation and function during the human cell cycle. Nat. Genet. 27:2001;48-54
100. Reshetnikova G., Barkan R., Popov B., Nikolsky N., Chang L.S. Disruption of the actin cytoskeleton leads to inhibition of mitogen-induced cyclin E expression, Cdk2 phosphorylation, and nuclear accumulation of the retinoblastoma protein-related p107 protein. Exp. Cell Res. 259:2000;35-53
101. Fukui R., Shibata N., Kohbayashi E., et al. Inhibition of smooth muscle cell migration by the p21 cyclin-dependent kinase inhibitor (Cip1). Atherosclerosis. 132:1997;53-59
102. INK4a tumour suppressor protein inhibits avb3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of avb3 to focal contacts. EMBO J. 18:1999;2106-2118
103. Kip1 by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. FASEB J. 15:2001;1877-1885
104. Kip1 in vascular smooth muscle cell migration. Circulation. 103:2001;2967-2972
105. Ohshima T., Gilmore E.C., Longenecker G., et al. Migration defects of cdk5(-/-) neurons in the developing cerebellum is cell autonomous. J. Neurosci. 19:1999;6017-6026
106. Gao C., Negash S., Wang H.S., et al. Cdk5 mediates changes in morphology and promotes apoptosis of astrocytoma cells in response to heat shock. J. Cell Sci. 114:2001;1145-1153
107. Humbert S., Dhavan R., Tsai L. p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J. Cell Sci. 113:2000;975-983
108. Xie Z., Sanada K., Samuels B.A., Shih H., Tsai L.H. Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration. Cell. 114:2003;469-482
109. Nikolic M. The molecular mystery of neuronal migration: FAK and Cdk5. Trends Cell Biol. 14:2004;1-5
110. Assoian R.K., Marcantonio E.E. The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J. Clin. Invest. 98:1996;2436-2439
111. Schwartz M.A., Assoian R.K. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J. Cell Sci. 114:2001;2553-2560
112. Strauss B.H., Chisholm R.J., Keeley F.W., Gotlieb A.I., Logan R.A., Armstrong P.W. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ. Res. 75:1994;650-658
113. Karim M.A., Miller D.D., Farrar M.A., et al. Histomorphometric and biochemical correlates of arterial procollagen gene expression during vascular repair after experimental angioplasty. Circulation. 91:1995;2049-2057
114. Coats W.D. Jr., Whittaker P., Cheung D.T., Currier J.W., Han B., Faxon D.P. Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Circulation. 95:1997;1293-1300
115. Koyama H., Raines E.W., Bornfeldt K.E., Roberts J.M., Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors. Cell. 87:1996;1069-1078
116. Zhu X., Ohtsubo M., Böhmer R.M., Roberts J.M., Assoian R.K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol. 133:1996;391-403
117. St Croix B., Sheehan C., Rak J.W., Florenes V.A., Slingerland J.M., Kerbel R.S. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J. Cell Biol. 142:1998;557-571
118. Huang S., Chen C.S., Ingber D.E. Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension. Mol. Biol. Cell. 9:1998;3179-3193
119. Waf1/Cip1. Atherosclerosis. 161:2002;105-112
120. Díez-Juan A., Andres V. Coordinate control of proliferation and migration by the p27Kip1/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. Circ. Res. 92:2003;402-410
121. D'Souza S.J., Vespa A., Murkherjee S., Maher A., Pajak A., Dagnino L. E2F-1 is essential for normal epidermal wound repair. J. Biol. Chem. 277:2002;10626-10632
122. Zhan Y., Kim S., Izumi Y., et al. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler. Thromb. Vasc. Biol. 23:2003;795-801
123. Sata M. Circulating vascular progenitor cells contribute to vascular repair, remodeling, and lesion formation. Trends Cardiovasc. Med. 13:2003;249-253
124. Hibbert B., Olsen S., O'Brien E. Involvement of progenitor cells in vascular repair. Trends Cardiovasc. Med. 13:2003;322-326
125. Marks A.R. Rapamycin: signaling in vascular smooth muscle. Transplant Proc. 35:2003;231S-233S
126. Burke S.E., Lubbers N.L., Chen Y.W., et al. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J. Cardiovasc. Pharmacol. 33:1999;829-835
127. Gallo R., Padurean A., Jayaraman T., et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 99:1999;2164-2170
128. Gregory C.R., Huie P., Billingham M.E., Morris R.E. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation. 55:1993;1409-1418
129. Gregory C.R., Huie P., Shorthouse R., et al. Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury. Transplant Proc. 25:1993;120-121
130. Meiser B.M., Billingham M.E., Morris R.E. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet. 338:1991;1297-1298
131. Poston R.S., Billingham M., Hoyt E.G., et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation. 100:1999;67-74
132. Suzuki T., Kopia G., Hayashi S., et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 104:2001;1188-1193
133. Kip1- independent pathway. Atherosclerosis. 172:2004;33-40
134. Elloso M.M., Azrolan N., Sehgal S.N., et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am. J. Transplant. 3:2003;562-569
135. Marks A.R. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N. Engl. J. Med. 349:2003;1307-1309
136. Sousa J.E., Sousa A.G., Costa M.A., Abizaid A.C., Feres F. Use of rapamycin-impregnated stents in coronary arteries. Transplant Proc. 35(Suppl. 3A):2003;S165-S170
137. Windecker S., Roffi M., Meier B. Sirolimus eluting stent: a new era in interventional cardiology? Curr. Pharm. Des. 9:2003;1077-1094
138. Mann M.J., Gibbons G.H., Tsao P.S., et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J. Clin. Invest. 99:1997;1295-1301
139. Morishita R., Gibbons G.H., Horiuchi M., et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle cell proliferation in vivo. Proc. Natl. Acad. Sci. U. S. A. 92:1995;5855-5859
140. Mann M.J., Whittemore A.D., Donaldson M.C., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 354:1999;1493-1498
141. Mangi A.A., Dzau V.J. Gene therapy for human bypass grafts. Ann. Med. 33:2001;153-155
142. Sedlacek H.H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol. 38:2001;139-170